ADC Therapeutics SA Files 8-K on Financials

TL;DR

ADC Therapeutics SA dropped an 8-K on Jan 13th - check their financials!

AI Summary

ADC Therapeutics SA filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Switzerland and its principal executive offices are located in Epalinges.

Why It Matters

This 8-K filing provides investors with crucial updates on ADC Therapeutics SA's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or unusual risks.

Key Players & Entities

• ADC Therapeutics SA (company) — Registrant
• January 13, 2025 (date) — Date of Earliest Event Reported
• Switzerland (location) — State of Incorporation and Principal Executive Offices
• Epalinges (location) — City of Principal Executive Offices

FAQ

Filing Documents

• dp223356_8k.htm (8-K) — 24KB
• dp223356_ex9901.htm (EX-99.1) — 46KB
• ex9901_001.jpg (GRAPHIC) — 314KB
• ex9901_002.jpg (GRAPHIC) — 717KB
• ex9901_003.jpg (GRAPHIC) — 240KB
• ex9901_004.jpg (GRAPHIC) — 255KB
• ex9901_005.jpg (GRAPHIC) — 404KB
• ex9901_006.jpg (GRAPHIC) — 193KB
• ex9901_007.jpg (GRAPHIC) — 327KB
• ex9901_008.jpg (GRAPHIC) — 371KB
• ex9901_009.jpg (GRAPHIC) — 335KB
• ex9901_010.jpg (GRAPHIC) — 168KB
• ex9901_011.jpg (GRAPHIC) — 281KB
• ex9901_012.jpg (GRAPHIC) — 403KB
• ex9901_013.jpg (GRAPHIC) — 376KB
• ex9901_014.jpg (GRAPHIC) — 378KB
• ex9901_015.jpg (GRAPHIC) — 307KB
• ex9901_016.jpg (GRAPHIC) — 290KB
• ex9901_017.jpg (GRAPHIC) — 199KB
• ex9901_018.jpg (GRAPHIC) — 298KB
• ex9901_019.jpg (GRAPHIC) — 441KB
• ex9901_020.jpg (GRAPHIC) — 482KB
• ex9901_021.jpg (GRAPHIC) — 259KB
• ex9901_022.jpg (GRAPHIC) — 300KB
• ex9901_023.jpg (GRAPHIC) — 389KB
• ex9901_024.jpg (GRAPHIC) — 216KB
• ex9901_025.jpg (GRAPHIC) — 249KB
• ex9901_026.jpg (GRAPHIC) — 95KB
• 0000950103-25-000411.txt ( ) — 11673KB
• adct-20250113.xsd (EX-101.SCH) — 3KB
• adct-20250113_lab.xml (EX-101.LAB) — 33KB
• adct-20250113_pre.xml (EX-101.PRE) — 22KB
• dp223356_8k_htm.xml (XML) — 4KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 13, 2025, ADC Therapeutics SA (the "Company") made available a corporate presentation that includes the preliminary information regarding ZYNLONTA net sales and regarding expenses for the year ended December 31, 2024. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in these Items and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate presentation dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADC Therapeutics SA Date: January 13, 2025 By: /s/ Peter J. Graham Name: Peter J. Graham Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR